Dasotraline Hydrochloride is a serotonin, dopamine, and norepinephrine reuptake inhibitor (SNDRI) primarily investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults. It helps improve focus, attention, and impulse control by modulating neurotransmitter levels in the brain. The compound has also shown promise in clinical trials for managing binge eating disorder through its regulation of dopamine and serotonin activity. Administered orally in a once-daily formulation, it features a long half-life (approximately 50-60 hours), supporting sustained therapeutic effects and suitability for long-term management. As a specialty chemical and active pharmaceutical ingredient (API), it is used in pharmaceutical research and development. Ongoing studies explore its potential in other psychiatric conditions, such as depression and anxiety. Use under medical supervision is essential, and it is not yet approved for clinical use in most jurisdictions.